Wockhardt Limited (WOCKPHARMA) Price & Analysis

Compare

4 Followers

WOCKPHARMA Stock Chart & Stats

₹1405.55

-₹25.55(-1.72%)

At close: Jan 08 4:00 PM EST

₹1405.55

-₹25.55(-1.72%)

Day’s Range― - ―

52-Week Range₹1,109.60 - ₹1,870.00

Previous CloseN/A

Volume236.67K

Average Volume (3M)24.00K

Market Cap

₹232.74B

Enterprise Value₹244.01B

Total Cash (Recent Filing)₹5.88B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)1027.5

Beta1.65

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)3.63

Shares Outstanding162,485,570

10 Day Avg. Volume15,364

30 Day Avg. Volume24,000

Financial Highlights & Ratios

PEG Ratio5.29

Price to Book (P/B)5.18

Price to Sales (P/S)7.42

P/FCF Ratio-85.35

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe consistent revenue growth indicates Wockhardt's ability to expand its market presence and enhance product adoption, which is crucial for long-term sustainability.

Gross Profit Margin ImprovementImproving gross profit margins suggest enhanced operational efficiency and cost management, which can lead to better profitability over time.

Leverage ReductionReduced leverage enhances financial stability and flexibility, allowing Wockhardt to better manage its capital structure and invest in growth opportunities.

Bears Say

Persistent Net LossesOngoing net losses undermine financial health and can limit the company's ability to reinvest in growth, posing a significant risk to long-term viability.

Negative Cash FlowNegative cash flow indicates that operational activities are not generating sufficient cash, which can strain liquidity and hinder investment in future growth.

Volatile Free Cash FlowVolatility in free cash flow suggests inconsistent operational efficiency, which can affect the company's ability to fund new projects and manage financial obligations.

Wockhardt Limited News

Wockhardt Opens SEBI-Mandated Window for Transfer of Physical Shares

Wockhardt Limited ( ($IN:WOCKPHARMA) ) has provided an announcement. Wockhardt Limited has informed stock exchanges that it has...

4d ago

Wockhardt earns independent ‘Aspiring’ ESG rating for 2025

Wockhardt Limited ( ($IN:WOCKPHARMA) ) has shared an update. Wockhardt Limited has been assigned an overall ESG score...

5d ago

Wockhardt’s Foviscu Matches Meropenem in Phase 3, Bolstering Antibiotic Pipeline

Wockhardt Limited ( ($IN:WOCKPHARMA) ) just unveiled an announcement. Wockhardt has reported that its novel intravenous antibiotic Foviscu...

28d ago

Wockhardt Receives Independently Assigned ESG Rating of 70 for 2025

An update from Wockhardt Limited ( ($IN:WOCKPHARMA) ) is now available. Wockhardt Limited has disclosed that CFC Finlease...

1M ago

Wockhardt Seeks Pan-European Approval for Novel Antibiotic WCK 5222

Wockhardt Limited ( ($IN:WOCKPHARMA) ) has provided an announcement. Wockhardt has filed a Marketing Authorisation Application with the...

2M ago

Wockhardt Submits NDA for Novel Antibiotic to U.S. FDA

Wockhardt Limited ( ($IN:WOCKPHARMA) ) has issued an update. Wockhardt Limited has submitted a New Drug Application to...

5M ago

Wockhardt Limited Reports Q1 2025 Financial Results

Wockhardt Limited ( ($IN:WOCKPHARMA) ) just unveiled an announcement. Wockhardt Limited announced the approval of its unaudited financial...

7M ago

Wockhardt’s Zaynich™ Successfully Treats Drug-Resistant Infection in US Pediatric Cancer Patient

Wockhardt Limited ( ($IN:WOCKPHARMA) ) just unveiled an announcement. Wockhardt Limited announced the successful treatment of a 15-year-old...

11M ago

WOCKPHARMA FAQ

What was Wockhardt Limited’s price range in the past 12 months?

Wockhardt Limited lowest stock price was ₹1109.60 and its highest was ₹1870.00 in the past 12 months.

What is Wockhardt Limited’s market cap?

Wockhardt Limited’s market cap is ₹232.74B.

When is Wockhardt Limited’s upcoming earnings report date?

Wockhardt Limited’s upcoming earnings report date is Jun 03, 2026 which is in 99 days.

How were Wockhardt Limited’s earnings last quarter?

Wockhardt Limited released its earnings results on Feb 10, 2026. The company reported ₹3.631 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.631.

Is Wockhardt Limited overvalued?

According to Wall Street analysts Wockhardt Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wockhardt Limited pay dividends?

Wockhardt Limited pays a Notavailable dividend of ₹9.218 which represents an annual dividend yield of N/A. See more information on Wockhardt Limited dividends here

What is Wockhardt Limited’s EPS estimate?

Wockhardt Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Wockhardt Limited have?

Wockhardt Limited has 162,485,570 shares outstanding.

What happened to Wockhardt Limited’s price movement after its last earnings report?

Wockhardt Limited reported an EPS of ₹3.631 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.086%.

Which hedge fund is a major shareholder of Wockhardt Limited?

Currently, no hedge funds are holding shares in IN:WOCKPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Wockhardt Limited

Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.